The anthracyclines: will we ever find a better doxorubicin?

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• Anthracyclines are a broad-spectrum class of antitumor drugs with significant efficacy in various human cancers.
• Doxorubicin (DOX) and daunorubicin (DNR) are foundational anthracyclines, with DOX differing slightly from DNR.
• Despite their effectiveness, anthracyclines are associated with significant toxicities, including cardiotoxicity, limiting their prolonged use.

Purpose of the Study:

• To review the development and efficacy of anthracycline analogs.
• To explore strategies for mitigating anthracycline-induced toxicity, particularly cardiotoxicity.
• To assess the current status and future directions of anthracycline-based cancer therapy.

Main Methods:

• Review of existing literature on anthracycline drugs and their analogs.
• Analysis of clinical data regarding efficacy and toxicity profiles.
• Evaluation of novel approaches to reduce drug-related adverse effects, such as dexrazoxane and modified administration protocols.

Main Results:

• While several DOX/DNR analogs exist, none have demonstrated superior antitumor efficacy compared to the original drugs.
• Strategies to reduce peak plasma levels of DOX, like prolonged infusion, are cumbersome but aim to minimize cardiotoxicity.
• Dexrazoxane shows promise in protecting against anthracycline-induced cardiomyopathy.
• Current research focuses on analogs designed to overcome multidrug resistance and on optimizing dosing for improved cytotoxicity with limited cardiotoxicity.

Conclusions:

• Doxorubicin (DOX) remains the anthracycline with the most proven cancer-fighting effect.
• Reducing anthracycline toxicity is a key focus, with promising developments in cardioprotective agents and analog design.
• Ongoing research aims to enhance the therapeutic index of anthracyclines for more effective and safer cancer treatment.